VEGF
Showing 1 - 25 of 3,749
Macular Edema Due to Type 2 Diabetes Trial in Hangzhou (Anti-VEGF, subthreshold micropulse laser)
Recruiting
- Macular Edema Due to Type 2 Diabetes Mellitus
- Anti-VEGF
- subthreshold micropulse laser
-
Hangzhou, Zhejiang, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
Feb 26, 2023
Glioblastoma Trial (Dose escalation of radiation dose beyond the therapeutic standard)
Not yet recruiting
- Glioblastoma
- Dose escalation of radiation dose beyond the therapeutic standard
- (no location specified)
May 13, 2023
Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)
Not yet recruiting
- Lung Adenocarcinoma
- +3 more
- Serplulimab and Bevacizumab injection
- (no location specified)
Dec 21, 2022
Diabetic Macular Edema, Pars Plana Vitrectomy, Conbercept Trial in Tianjin (Vitrectomy combined with ILM peeling, Conbercept
Not yet recruiting
- Diabetic Macular Edema
- +2 more
- Vitrectomy combined with ILM peeling
- Conbercept intravitreal injection
-
Tianjin, Tianjin, ChinaTianjin medical university eye hosipital
Feb 14, 2023
Recurrent Brain Tumor Trial in Houston (biological, other, radiation)
Active, not recruiting
- Recurrent Brain Neoplasm
- Bevacizumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Advanced Cancer Trial in Houston (Dasatinib, Bevacizumab, Paclitaxel)
Completed
- Advanced Cancer
- Dasatinib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Nov 21, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Completed
- Platinum-Resistant Fallopian Tube Carcinoma
- +8 more
- Bevacizumab
- Irinotecan Sucrosofate
-
Chicago, IllinoisNorthwestern University
Dec 21, 2022
Pathogenesis and Severity of COVID-19 Disease
Recruiting
- COVID-19 Disease
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Nov 8, 2022
Iris Trial in Assiut (Immunohistochemistry analysis)
Not yet recruiting
- Iris
- Immunohistochemistry analysis
-
Assiut, EgyptHassan Lotfy
Jul 29, 2022
Renal Cell Carcinoma Trial in Chapel Hill (Survey Questionnaire)
Recruiting
- Renal Cell Carcinoma
- Survey Questionnaire
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Oct 19, 2022
Uveitis, Macular Edema, Vascular Endothelial Growth Factor Trial in Beijing (intravitreal injection of Conbercept)
Terminated
- Uveitis
- +3 more
- intravitreal injection of Conbercept
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital (PUMCH)
Oct 24, 2022
Malignant Tumor Trial in Shanghai (PM8002)
Recruiting
- Malignant Neoplasm
-
Shanghai, Shanghai, ChinaShanghai Orient Hospital
Jun 25, 2023
Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo
Not yet recruiting
- Fallopian Tube Carcinosarcoma
- +10 more
- Bevacizumab
- +4 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 29, 2022
Clear Cell Kidney Cancer, Kidney Cancer, Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations Trial (Axitinib 5 MG)
Available
- Clear Cell Kidney Cancer
- +2 more
- Axitinib 5 MG
- (no location specified)
Jul 3, 2023
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage, Tractional Retinal Detachment Trial in Monastir (Bevacizumab Injection
Recruiting
- Proliferative Diabetic Retinopathy
- +2 more
- Bevacizumab Injection [Avastin]
- Peripheral Retinal Cryoapplication
-
Monastir, TunisiaFattouma Bourguiba University Hospital - Ophthalmology Departmen
Aug 22, 2022
Pheochromocytoma, Paraganglioma Trial in New York (Axitinib)
Recruiting
- Pheochromocytoma
- Paraganglioma
-
New York, New YorkColumbia University Irving Medical Center
Oct 5, 2022
Proliferative Diabetic Retinopathy Trial in Beijing (proactive Anti-VEGF (conbercept) use, passive Anti-VEGF (conbercept) use)
Recruiting
- Proliferative Diabetic Retinopathy
- proactive Anti-VEGF (conbercept) use
- passive Anti-VEGF (conbercept) use
-
Beijing, Beijing, ChinaPeking University Third Hospital
Dec 13, 2022
Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial
Recruiting
- Resectable Hepatocellular Carcinoma
- +4 more
- Atezolizumab
- +2 more
-
Houston, Texas
- +1 more
Oct 12, 2022
Metastatic Colorectal Carcinoma, Metastatic Malignant Tumor in the Liver, Stage IV Colorectal Cancer AJCC v8 Trial (biological,
Not yet recruiting
- Metastatic Colorectal Carcinoma
- +3 more
- Bevacizumab
- +11 more
- (no location specified)
May 9, 2023